Biotech leaders call on peers to lobby for IRA change

A group of prominent biotech investors and CEOs are circulating a letter warning that provisions in the Inflation Reduction Act will, if not changed, have dire consequences for patients and innovative drug developers.

The letter, written by Peter Kolchinsky, managing partner at RA Capital Management and Peter Thompson, general partner at OrbiMed Advisors, focuses on the the nine-year threshold for unregulated pricing of small molecules and other drugs approved under the NDA pathway. ...